Chen Bihua's Form 4 filing
MoonLake Immunotherapeutics (MLTX) · filed Apr 7, 2022
- Accession no.
- 0001213900-22-018749
- Filed
- Apr 7, 2022
- Trade date
- Apr 5, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market purchases total $28.5M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Chen BihuaCIK 0001599214 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 5, 2022 | Class A Ordinary Shares | CConversionAcquired | +2,785,000 | $0.00 | $0 | 3,215,000 | Indirect | |
| Apr 5, 2022 | Class A Ordinary Shares | PPurchaseAcquired | +2,850,000 | $10.00 | +$28,500,000 | 2,850,000 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 5, 2022 | Class A Ordinary Shares | CConversionDisposed | −2,785,000 | – | – | 0 | Indirect |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.